Rapid regression of Kaposi's sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixdose antiretroviral combination therapy

Infection. 2016 Feb;44(1):103-6. doi: 10.1007/s15010-015-0792-8. Epub 2015 May 7.

Abstract

Introduction: Kaposi's sarcoma (KS) is a rare vascular tumor that may occur in a severe, rapidly progressive form, namely in HIV/AIDS patients. HIV-associated KS mainly affects the skin and mucous membranes.

Case presentation: We report about an HIV-positive patient who presented with an exophytic growing tumor in the region of the hard palate and severe problems regarding his dental status. Histological examination revealed evidence of AIDS-related KS. Antiretroviral therapy initiation with elvitegravir/cobicistat/emtricitabine(FTC)/tenofovirdisoproxilfumarat (E/c/F/T-fix dose combination) resulted in rapid complete remission of the KS within 2 months.

Conclusion: In this case of a treatment-naive HIV-infected patient with coexisting KS, antiretroviral therapy with E/c/FTC/TDF was very well suited to achieve rapid complete remission of KS.

Keywords: Elvitegravir; HIV; Kaposi.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods*
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Palatal Neoplasms / pathology*
  • Palate, Hard / pathology*
  • Quinolones / therapeutic use*
  • Sarcoma, Kaposi / pathology*
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Quinolones
  • elvitegravir